Larger tumors are associated with inferior progression‐free survival of first‐line EGFR‐tyrosine kinase inhibitors and a lower abundance of EGFR mutation in patients with advanced non‐small cell lung cancer

The impact of primary tumor size on the therapeutic outcomes of EGFR‐tyrosine kinase inhibitors (TKIs) in advanced non‐small cell lung cancer (NSCLC) with EGFR mutation remains unclear.

[1]  Qinghua Xu,et al.  Consolidative Local Ablative Therapy Improves the Survival of Patients With Synchronous Oligometastatic NSCLC Harboring EGFR Activating Mutation Treated With First‐Line EGFR‐TKIs , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[2]  Mengzhao Wang,et al.  Efficacy of icotinib in advanced lung squamous cell carcinoma , 2018, Cancer medicine.

[3]  V. Gebski,et al.  The Value of Early Depth of Response in Predicting Long‐Term Outcome in EGFR‐Mutant Lung Cancer , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[4]  A. Gemma,et al.  Phase III study comparing gefitinib monotherapy (G) to combination therapy with gefitinib, carboplatin, and pemetrexed (GCP) for untreated patients (pts) with advanced non-small cell lung cancer (NSCLC) with EGFR mutations (NEJ009). , 2018 .

[5]  Jih-Hsiang Lee,et al.  Best Response According to RECIST During First‐line EGFR‐TKI Treatment Predicts Survival in EGFR Mutation‐positive Non–Small‐cell Lung Cancer Patients , 2018, Clinical lung cancer.

[6]  S. Ren,et al.  Distinct clinicopathologic features, genomic characteristics and survival of central and peripheral pulmonary large cell neuroendocrine carcinoma: From different origin cells? , 2018, Lung cancer.

[7]  F. Hirsch,et al.  Comprehensive Analysis of EGFR‐Mutant Abundance and Its Effect on Efficacy of EGFR TKIs in Advanced NSCLC with EGFR Mutations , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[8]  S. Ren,et al.  Continuation of gefitinib plus chemotherapy prolongs progression-free survival in advanced non-small cell lung cancer patients who get acquired resistance to gefitinib without T790M mutations. , 2017, Journal of thoracic disease.

[9]  S. Kobayashi,et al.  Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomes. , 2017, Lung cancer.

[10]  H. Ditzel,et al.  Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC , 2017, Journal of the National Cancer Institute.

[11]  Matteo Canale,et al.  Impact of TP53 Mutations on Outcome in EGFR-Mutated Patients Treated with First-Line Tyrosine Kinase Inhibitors , 2016, Clinical Cancer Research.

[12]  A. Nicholson,et al.  The IASLC Lung Cancer Staging Project: Proposals for Coding T Categories for Subsolid Nodules and Assessment of Tumor Size in Part‐Solid Tumors in the Forthcoming Eighth Edition of the TNM Classification of Lung Cancer , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[13]  Ho Yun Lee,et al.  Survival outcome assessed according to tumor burden and progression patterns in patients with epidermal growth factor receptor mutant lung adenocarcinoma undergoing epidermal growth factor receptor tyrosine kinase inhibitor therapy. , 2015, Clinical lung cancer.

[14]  F. Hirsch,et al.  The Bim deletion polymorphism clinical profile and its relation with tyrosine kinase inhibitor resistance in Chinese patients with non–small cell lung cancer , 2014, Cancer.

[15]  Jingyun Shi,et al.  T790M mutation is associated with better efficacy of treatment beyond progression with EGFR-TKI in advanced NSCLC patients. , 2014, Lung cancer.

[16]  Yi-long Wu,et al.  Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. , 2014, The Lancet. Oncology.

[17]  D. Gerber,et al.  Baseline tumour measurements predict survival in advanced non-small cell lung cancer , 2013, British Journal of Cancer.

[18]  K. Nishio,et al.  Hypoxia induces gefitinib resistance in non‐small‐cell lung cancer with both mutant and wild‐type epidermal growth factor receptors , 2012, Cancer science.

[19]  Kathryn Trinkaus,et al.  Prognostic Significance of Tumor Size in Patients with Stage III Non–Small-Cell Lung Cancer: A Surveillance, Epidemiology, and End Results (SEER) Survey from 1998 to 2003 , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[20]  E. Felip,et al.  Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. , 2012, The Lancet. Oncology.

[21]  Jun Ma,et al.  Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. , 2011, The Lancet. Oncology.

[22]  Masahiro Tsuboi,et al.  International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[23]  J. Abbruzzese,et al.  F1000 highlights , 2009, JAMA.

[24]  I. Tannock,et al.  Drug resistance and the solid tumor microenvironment. , 2007, Journal of the National Cancer Institute.

[25]  R K Jain,et al.  Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. , 1990, Cancer research.

[26]  Liu Yan-hui,et al.  Interpretation of Pathological Perspective——International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma , 2011 .

[27]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.